

1. A composition comprising:  
a prodrug of florfenicol and a pharmaceutically acceptable carrier, provided in an injectable composition.
2. The composition of claim 1 wherein the prodrug of florfenicol is present in the composition at a concentration of at least 200 mg/ml.
3. The composition of claim 2 wherein the prodrug of florfenicol is present in the composition at a concentration of about 300 mg/ml.
4. The composition of claim 1 wherein the prodrug comprises an esterified form of florfenicol.
5. The composition of claim 4 wherein the prodrug is selected from the group consisting of one or a combination of: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nonanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate.
6. The composition of claim 5 wherein the composition is selected from the group consisting of one or a combination of: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol hexanoate, florfenicol phthalate.
7. The composition of claim 5 wherein the prodrug is converted into florfenicol in vivo by the action of an esterase.
8. A compound selected from the group consisting of: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate,

florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate.

9. A pharmaceutical composition for administration to a mammal comprising a compound of claim 8 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9 wherein the compound is selected from the group consisting of: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol hexanoate, florfenicol octanoate, florfenicol decanoate, florfenicol dodecanoate, and florfenicol phthalate.

11. A method of administering florfenicol to a mammal comprising:  
administering a composition containing a prodrug of florfenicol to the mammal, wherein the prodrug is converted in vivo by endogenous enzymes into florfenicol.

12. The method of claim 11 wherein the composition is administered by injection.

13. The method of claim 11 wherein the composition forms a drug depot in the mammal when injected.

14. The method of claim 11 wherein the prodrug is present in the composition at a concentration of at least 250 mg/ml.

15. The method of claim 14 wherein the prodrug is selected from the group consisting of one or a combination of: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate.

16. The composition of claim 15 wherein the prodrug is selected from the group consisting of one or a combination of: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol hexanoate, and florfenicol phthalate.

17. The composition of claim 15 wherein the prodrug is converted into the florfenicol in vivo by the action of one or more esterases.

18. The method of claim 11 wherein the mammal is selected from the group consisting of: a bovine, an equine, an ovine, a porcine, a canine, and a feline.

19. The method of claim 12 wherein the prodrug is injected into the mammal intramuscularly.

20. A method of administering florfenicol to a mammal comprising:  
injecting into the mammal a composition comprising a compound selected from the group consisting of one or a combination of: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nonanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate;

wherein the one or more compounds is/are converted into florfenicol in vivo by the action of one or more endogenous esterases.

21. The method of claim 20 wherein the one or more compounds are selected from the group consisting of one or a combination of: florfenicol acetate, florfenicol butyrate, florfenicol hexanoate, florfenicol propionate, and florfenicol phthalate.

22. The method of claim 20 wherein the one or more compounds is/are present in the composition at a concentration of at least 250 mg/ml.

23. The method of claim 20 wherein the mammal is selected from the group consisting of: a bovine, an equine, an ovine, a porcine, a canine, and a feline.

24. The method of claim 23 wherein the formulation is injected into the mammal intra-muscularly.